Drug1st-line biologic line
Dupilumab
Anti–IL-4Rα monoclonal antibody (blocks IL-4 and IL-13)
- Response rate
- ~75% polyp reduction
- Onset
- 4–8 weeks
- Route
- SC 300mg every 2 weeks
- Line
- 1st-line biologic
- IgM effect
- Reduces polyp score by ~2 points (NPS)
- Evidence level
- green
- Trial phase
- Phase 4
Evidence summary
Blocks both IL-4 and IL-13 signalling via IL-4Rα. SINUS-24 and SINUS-52 trials demonstrated significant improvements in nasal polyp score (NPS), nasal congestion, Lund-Mackay CT score, SNOT-22, and olfaction (UPSIT). FDA-approved 2019. The most broadly effective biologic with consistent benefit across multiple outcomes.
Approved indications
Conditions for which Dupilumab has regulatory approval (not specific to rare diseases covered here):
Atopic DermatitisModerate-to-Severe AsthmaChronic Rhinosinusitis with Nasal PolypsEosinophilic EsophagitisPrurigo Nodularis
Drug identifiers
| DrugBank | DB12293 ↗ |
| ATC Code | D11AH05 |
| Open Targets | CHEMBL3707341 ↗ |